Table 1.
Baseline characteristics of included participants (n = 59) and comparison between participants with at least one follow-up assessment (n = 48) and those lost to follow-up (n = 11)
| Characteristics | At least one follow-up assessment | Lost to follow-up | P | Total |
|---|---|---|---|---|
| n (%) or median [IQR] | n (%) or median [IQR] | n (%) or median [IQR] | ||
| Gender (Male) | 37 (77%) | 8 (73%) | 0.76 | 45 (76%) |
| Age (years) | 43.5 [35–47.5] | 38 [33–45] | 0.17 | 41 [35–47] |
| Education (< High School Diploma) | 32 (67%) | 11 (100%) | 0.03 | 43 (73%) |
| Unstable housing (Yes) | 16 (33%) | 11 (100%) | < 0.001 | 27 (46%) |
| Having slept in the streeta (Yes) | 10 (21%) | 5 (45%) | 0.09 | 12 (25%) |
| Employment (Yes) | 9 (19%) | 1 (9%) | 0.67 | 10 (17%) |
| Injection in public places (Yes) | 16 (13%) | 4 (36%) | 0.08 | 10 (17%) |
| Daily drug injectiona (Yes) | 36 (77%) | 8 (73%) | 0.30 | 44 (75%) |
| Number of daily injectionsa | 4 [2–5] | 3 [2–4] | 0.59 | 4 [2–5] |
| Drugs injecteda | ||||
| Heroin | 9 (19%) | 3 (73%) | 0.53 | 12 (20%) |
| Buprenorphine | 20 (42%) | 3 (27%) | 0.38 | 23 (39%) |
| Morphine sulfate | 19 (40%) | 5 (45%) | 0.72 | 24 (41%) |
| Cocaine | 34 (71%) | 9 (82%) | 0.46 | 43 (73%) |
| Methylphenidate | 3 (6%) | 2 (18%) | 0.23 | 5 (9%) |
| Current opioid agonist treatment (Yes) | 35 (73%) | 9 (82%) | 0.71 | 44 (76%) |
| History of HCV infection | 0.94 | |||
| No | 21 (45%) | 5 (45%) | 26 (45%) | |
| Yes, cured | 15 (32%) | 3 (27.5%) | 18 (31%) | |
| Yes, current | 11 (23%) | 3 (27.5%) | 14 (24%) | |
| Injecting-related complications (lifetime) | ||||
| Abscesses and other SSTI | 32 (67%) | 10 (91%) | 0.15 | 42 (71%) |
| Cotton fever | 36 (75%) | 9 (82%) | 0.63 | 45 (76%) |
| Endocarditis or sepsis | 5 (10%) | 1 (9%) | 0.90 | 6 (10%) |
Abbreviations: IQR Interquartile range, HCV Hepatitis C Virus, SSTI Skin and soft tissue infections
aPrevious month